48 Results

People

  1. Gounder
    Gounder
  2. Konner
    Konner
  3. Abrey
    Abrey
  4. Chapman
    Chapman
  5. Dickson
    Dickson
  6. Francis
    Francis
  7. Grimm
    Grimm
  8. Lendvai
    Lendvai
  9. Marr
    Marr
  10. Momtaz
    Momtaz

Groups

  1. Department of Medicine (30)
  2. Solid Tumor Oncology Division (23)
  3. Hematologic Malignancies, Division of (9)
  4. Center for Hematologic Malignancies (8)
  5. Surgery (8)
  6. Gynecologic Medicine Service (5)
  7. Gynecology Disease Management Team (5)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (4)
  9. GDMT, Medicine (4)
  10. Gastrointestinal Oncology Service (4)
  1. "blurred vision"
Formats
  1. Journal Article (41)
  2. Review (4)
  3. Research Letter (3)
Groups
  1. Department of Medicine (30)
  2. Solid Tumor Oncology Division (23)
  3. Hematologic Malignancies, Division of (9)
  4. Center for Hematologic Malignancies (8)
  5. Surgery (8)
  6. Gynecologic Medicine Service (5)

More Groups

People
  1. Jasmine Francis (3)
  2. Jason Konner (3)
  3. Mrinal Gounder (3)
  4. Paul Chapman (3)
  5. Anas Younes (2)
  6. Brian Marr (2)

More People

Years
  1. 2025 (2)
  2. 2024 (3)
  3. 2023 (2)
  4. 2022 (3)
  5. 2021 (2)
  6. 2020 (6)

More Years

Publications
  1. Clinical Cancer Research (4)
  2. Journal of Clinical Oncology (3)
  3. Lancet Oncology (3)
  4. American Journal of Ophthalmology Case Reports (2)
  5. Cancer (2)
  6. Gynecologic Oncology (2)

More Publications

Publishers
  1. Elsevier Inc. (9)
  2. Nature Publishing Group (5)
  3. American Association for Cancer Research (4)
  4. American Society of Clinical Oncology (4)
  5. Elsevier Science, Inc. (4)
  6. Wiley Blackwell (4)

More Publishers

Results (48)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors
    Journal Article

    Schram, A. M.; Boni, V.; Adjei, A. A.; Olszanski, A. J.; Vieito, M.; Francis, J. H.; Kurman, M.; Ahsan, J. M.; Tomkinson, B.; Garralda, E.
    ESMO Open (2025)

    Fulltext@MSK | Save
  • MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: A phase I trial
    Journal Article

    Gounder, M.; Johnson, M.; Heist, R. S.; Shapiro, G. I.; Postel-Vinay, S.; Wilson, F. H.; Garralda, E.; Wulf, G.; Almon, C.; Nabhan, S.; more...
    Nature Communications (2025)

    Fulltext@MSK | Save
  • Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab
    Journal Article

    Lochrin, S. E.; Buonocore, D. J.; Young, R. J.; Kaley, T. J.; Postow, M. A.; Wolchok, J. D.; Shoushtari, A. N.; Momtaz, P.; Betof Warner, A. S.; Callahan, M. K.
    Pigment Cell & Melanoma Research (2024)

    Fulltext@MSK | Save
  • Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells
    Journal Article

    Yankelevich, M.; Thakur, A.; Modak, S.; Chu, R.; Taub, J.; Martin, A.; Schalk, D.; Schienshang, A.; Whitaker, S.; Rea, K.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Ocular toxicities of fibroblast growth factor receptor inhibitors: A review
    Review

    Hsu, J.; Francis, J. H.; Ahmad, S.
    Survey of Ophthalmology (2024)

    Fulltext@MSK | Save
  • Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
    Journal Article

    Nooka, A. K.; Cohen, A. D.; Lee, H. C.; Badros, A.; Suvannasankha, A.; Callander, N.; Abdallah, A. O.; Trudel, S.; Chari, A.; Libby, E. N.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Cannabinoids as a potential alternative to opioids in the management of various pain subtypes: Benefits, limitations, and risks
    Review

    Ang, S. P.; Sidharthan, S.; Lai, W.; Hussain, N.; Patel, K. V.; Gulati, A.; Henry, O.; Kaye, A. D.; Orhurhu, V.
    Pain and Therapy (2023)

    Fulltext@MSK | Save
  • Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: A phase II risk-adapted design
    Journal Article

    Kumar, A.; Casulo, C.; Joffe, E.; Moskowitz, C.; Gerecitano, J.; Moskowitz, A.; Younes, A.; Drullinsky, P.; Drill, E.; Choma, M.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Selinexor in advanced, metastatic dedifferentiated liposarcoma: A multinational, randomized, double-blind, placebo-controlled trial
    Journal Article

    Gounder, M. M.; Razak, A. A.; Somaiah, N.; Chawla, S.; Martin-Broto, J.; Grignani, G.; Schuetze, S. M.; Vincenzi, B.; Wagner, A. J.; Chmielowski, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibition
    Journal Article

    Foulsham, W.; Edghill, B. Z.; Canestraro, O. D. J.; Makker, V.; Konner, J.; Abramson, D. H.; Francis, J. H.
    American Journal of Ophthalmology Case Reports (2022)

    Fulltext@MSK | Save